World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
95
Citations
52715
World Ranking
9865
National Ranking
5072

Peter J. O'Dwyer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter J. O'Dwyer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 459 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter J. O'Dwyer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter J. O'Dwyer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter J. O'Dwyer is affiliated with the University of Pennsylvania in the United States. Their research spans multiple areas within medicine and biomedical sciences, with a strong focus on oncology and molecular biology. Over their career, they have contributed extensively to academic literature in these fields.

The scientist has published research in the following fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, their subfields of study include:

  • Oncology
  • Molecular Biology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Surgery

O'Dwyer's main research topics cover a wide range of cancer-related subjects:

  • Cancer Genomics and Diagnostics
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Gastric Cancer Management and Outcomes
  • PI3K/AKT/mTOR signaling in cancer
  • Chronic Lymphocytic Leukemia Research

Their publication record includes contributions to significant journals, with frequent publications in:

  • Journal of Clinical Oncology
  • JCO Precision Oncology
  • Clinical Cancer Research
  • Cancer Research
  • Annals of Oncology

Among recent papers authored or coauthored by O'Dwyer are:

  • "Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)", 2020, Journal of Clinical Oncology
  • "Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H", 2020, Journal of Clinical Oncology
  • "Service Robots in the Healthcare Sector", 2021, Robotics
  • "Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)", 2022, Journal of Clinical Oncology
  • "Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W", 2020, Journal of Clinical Oncology

O'Dwyer has collaborated frequently with other researchers, including:

  • Stanley R. Hamilton
  • Lyndsay N. Harris
  • Keith T. Flaherty
  • Lisa M. McShane
  • Robert J. Gray

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Inhibition of mutated, activated BRAF in metastatic melanoma.

    Keith T. Flaherty;Igor Puzanov;Kevin B. Kim;Antoni Ribas

  • Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

    Bruce J. Giantonio;Paul J. Catalano;Neal J. Meropol;Peter J. O'Dwyer

  • CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

    Gregory L. Beatty;Elena G. Chiorean;Matthew P. Fishman;Babak Saboury

  • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

    Mark J. Ratain;Tim Eisen;Walter M. Stadler;Keith T. Flaherty

  • High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

    Andrew K. Godwin;Alton Meister;Peter J. O'Dwyer;Chin Shiou Huang

  • Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy

    Mara H. Sherman;Ruth T. Yu;Dannielle D. Engle;Ning Ding

  • Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Daniel J. Klionsky;Kotb Abdelmohsen;Akihisa Abe;Joynal Abedin

  • Phase II Trial of Sorafenib in Advanced Thyroid Cancer

    Vandana Gupta-Abramson;Andrea B. Troxel;Anoma Nellore;Kanchan Puttaswamy

  • Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

    Scott Kopetz;Jayesh Desai;Emily Chan;Joel Randolph Hecht

  • Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

    Robert H. Vonderheide;Keith T. Flaherty;Magi Khalil;Molly S. Stumacher

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group

    Elizabeth Poplin;Yang Feng;Jordan Berlin;Mace L. Rothenberg

  • Combined-Modality Treatment for Resectable Metastatic Colorectal Carcinoma to the Liver: Surgical Resection of Hepatic Metastases in Combination With Continuous Infusion of Chemotherapy—An Intergroup Study

    M. Margaret Kemeny;Sudeshna Adak;Bruce Gray;John S. Macdonald

  • Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

    Roy S. Herbst;S. Gail Eckhardt;Razelle Kurzrock;Scot Ebbinghaus

  • Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer

    Ryan B. Corcoran;Thierry Andre;Chloe E. Atreya;Jan H.M. Schellens

  • A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

    Gregory L. Beatty;Drew A. Torigian;E. Gabriela Chiorean;Babak Saboury

  • A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

    Myrna R. Rosenfeld;Xiaobu Ye;Jeffrey G. Supko;Serena Desideri

  • Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

    Mark Sausen;Jillian Phallen;Vilmos Adleff;Siân Jones

  • Etoposide (VP-16-213). Current status of an active anticancer drug.

    P J O'Dwyer;B Leyland-Jones;M T Alonso;S Marsoni

Frequent Co-Authors

Keith T. Flaherty
Keith T. Flaherty Harvard University
Al B. Benson
Al B. Benson Northwestern University
Stanley R. Hamilton
Stanley R. Hamilton City Of Hope National Medical Center
Thomas C. Hamilton
Thomas C. Hamilton Fox Chase Cancer Center
Robert F. Ozols
Robert F. Ozols Fox Chase Cancer Center
Mark A. Rosen
Mark A. Rosen University of Pennsylvania
Paul J. Catalano
Paul J. Catalano Harvard University
Daniel G. Haller
Daniel G. Haller University of Pennsylvania
Carlos L. Arteaga
Carlos L. Arteaga The University of Texas Southwestern Medical Center
Angela DeMichele
Angela DeMichele University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to a wide range of healthcare careers. For students seeking flexibility and affordability, online degrees in the medical field are becoming increasingly popular. Roles such as medical coder, nurse, nurse practitioner, or nurse educator are now more accessible than ever through accredited online programs.

Medical coding certification online programs provide a fast track into healthcare administration, a field in high demand for accuracy and up-to-date knowledge of billing systems. For those aiming to become advanced practice nurses, the cheapest online FNP program options make it easier to balance study, work, and family commitments.

Aspiring registered nurses can find affordable nursing programs online, helping to reduce the financial barrier to entry in this respected profession. For nurses interested in leadership or academic roles, a doctorate in nursing education online programs unlocks further career advancements without the need to relocate.

These accessible online learning paths can help you reach your healthcare career goals while maintaining flexibility and controlling costs.

Best Scientists Citing Peter J. O'Dwyer

Trending Scientists

Recently Published Articles